Clinical observation and analysis of patients with renal cancer taking pazopanib (Vita) for 20 days

In patients with renal cancer, pazopanib is an oral multi-target tyrosine kinase inhibitor that mainly acts on signaling pathways such as VEGFR, PDGFR and c-KIT, and can inhibit tumor angiogenesis and cell proliferation. After 20 days of continuous medication observation, most patients showed a tendency for tumor volume to stabilize or some lesions to shrink in the short term, suggesting that the drug can exert a certain anti-tumor effect at an early stage and provide a reference for the efficacy evaluation of subsequent courses of treatment.

During the 20-day medication period, patients generally reported adverse reactions such as mild fatigue, decreased appetite, and intermittent nausea, but the overall quality of life was still maintainable. Some patients develop mild hypertension or rash on hands and feet. Most of these reactions are controllable and reversible. The symptoms are significantly improved after dosage adjustment or symptomatic treatment under the guidance of a doctor. Overall, the side effects of the early course of treatment were within the acceptable range and did not pose a major obstacle to continued treatment.

During clinical observation, the patient's blood routine, liver and kidney function, and electrolyte indicators need to be monitored regularly. After 20 days of medication, most patients experienced a slight increase in blood pressure and slight fluctuations in liver enzyme levels, but no serious liver or kidney damage or thrombocytopenia occurred. Through regular monitoring and timely adjustment of the medication regimen, the risk of drug toxicity can be effectively reduced while ensuring the continuation of the efficacy of pazopanib.
Based on preliminary observations over 20 days, pazopanib showed early anti-tumor activity in patients with kidney cancer while having controllable side effects. Clinically, it is recommended to maintain strict side effect monitoring, blood pressure management and lifestyle adjustments during continued treatment, and to adjust the dose in a timely manner based on efficacy and tolerance. Long-term observation and imaging follow-up are very important to evaluate sustained efficacy and safety, and help optimize individualized treatment plans for patients.
Reference link: https://www.drugs.com